Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation
Journal of Clinical and Experimental Hematopathology · 2025
DOI: 10.3960/jslrt.25001 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2025. Verfasst von Daiki Hirano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. Hauptthemen laut MEDLINE: Bortezomib, Peripheral Blood Stem Cell Transplantation, Cryoglobulinemia, Smoldering Multiple Myeloma. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A 52-year-old male developed multiple skin ulcers/purpura in the bilateral lower limbs. A detailed examination led to a diagnosis of type I cryoglobulinemia-related skin lesions, with smoldering multiple myeloma (SMM) as a background disease. After 5 years, dermal symptoms became severe. Although there were no multiple myeloma (MM)-related symptoms other than the skin, induction therapy with bortezomib and dexamethasone (BD) was performed. Since dermal symptoms and SMM responded well to treatment, high-dose chemotherapy (melphalan) with autologous peripheral blood stem cell transplantation (ASCT) was subsequently performed. There were no serious treatment-associated adverse events. In addition, a marked response was achieved, and the disease state was stable for ≥24 months. Only a few similar case reports have been reported to date. According to a recent study, when type I cryoglobulinemia becomes symptomatic, the treatment of respective hematological diseases as a background factor and patient-matched individualized treatment should be performed. The present case suggests that it is a feasible, safe and effective treatment strategy to consider the eligibility for high-dose chemotherapy with ASCT and then perform it, even for SMM-associated type I cryoglobulinemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
- Department of Pathology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
- Department of Dermatology, Holy Spirit Hospital, Nagoya, Japan.
- Division of Rheumatology, Department of Internal Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Zitieren
APA
Hirano, D., Iida, H., Iwakoshi, A., Sunohara, A., Suzuki, M., Suzuki, Y., Imahashi, N., Adachi, T., & Nagai, H. (2025). Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.25001
Vancouver
Hirano D, Iida H, Iwakoshi A, Sunohara A, Suzuki M, Suzuki Y, et al. Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation. Journal of Clinical and Experimental Hematopathology. 2025. doi:10.3960/jslrt.25001
BibTeX
@article{Hirano2025,
author = {Hirano, Daiki and Iida, Hiroatsu and Iwakoshi, Akari and Sunohara, Akiyo and Suzuki, Michita and Suzuki, Yasuhiro and Imahashi, Nobuhiko and Adachi, Tatsuya and Nagai, Hirokazu},
title = {Successful treatment of smoldering multiple myeloma-associated type I cryoglobulinemia with bortezomib and autologous peripheral blood stem cell transplantation},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2025},
doi = {10.3960/jslrt.25001}
}
EUVIMED